

MedStar Health, Inc.

POLICY AND PROCEDURE MANUAL

Policy Number: MP.052.MH
Last Review Date: 05/10/2018
Effective Date: 07/01/2018

MP.052.MH – Bladder Cancer Biomarker Tests

This policy applies to the following lines of business:

- ✓ MedStar Employee (Select)
- ✓ MedStar CareFirst PPO

MedStar Health considers **Bladder Cancer Biomarker Tests** medically necessary for the following indications:

UroVysion™ is considered medically necessary when performed in conjunction with current standard diagnostic procedures (i.e. cystoscopy and cytology) for either of the following conditions:

- a. Diagnosis of person with hematuria suspected of having bladder carcinoma
- b. Subsequent monitoring for tumor recurrence

Limitations

- 1) UroVysion™ is considered not medically necessary when cystoscopy/cytology results are diagnostic for bladder cancer.
- 2) Bladder tumor marker testing is considered experimental/investigational for population-based screening of asymptomatic patients for bladder cancer.

Background

According to the National Cancer Institute, bladder cancer is the fourth most common cancer in men and ninth most common cancer in women in the United States. The American Urological Association reports that more than 60,000 new cases of bladder cancer are diagnosed each year in the United States, accounting for nearly 13,000 deaths annually. Bladder cancer, also known as transitional cell carcinoma (TCC), is a heterogeneous disease, and the most common malignancy of the urinary tract (>90% of the cases). Several urine based bladder tumor marker tests have been developed as an adjunct to cytology and cystoscopy for the diagnosis and follow-up of patients with TCC. Some of the U.S. Food & Drug Administration's (FDA) approved bladder tumor detection tests include:

Tests for detecting urinary bladder tumor-associated antigen (BTA):

MP.052.MH – Bladder Cancer Biomarker Tests

Policy Number: MP.052.MH
Last Review Date: 05/10/2018
Effective Date: 07/01/2018

- The Bard BTA (bladder tumor antigen) Test Kit - this test was the first approved by the FDA November 29, 1995. Its indication was expanded in 1998 to include home use.
- The BTA TRAK test – this test was FDA approved April 15, 1998 and is completed in the laboratory.

Tests for detecting nuclear matrix protein 22 (NMP22):

- Matritech NMP22 Test Kit – this test was FDA approved July 2, 1996.
- NMP22 BladderCheck Test – this test was FDA approved July 30, 2002. This test can be used in the doctor’s office or at home.

UroVysion™ fluorescent in situ hybridization (FISH) test by Abbott – in 2001 (August 3, 2001) the FDA granted premarket approval for this Class II test for monitoring tumor recurrence in patients with a history of bladder cancer and in 2005 (January 24, 2005) also as an aid for initial diagnosis of bladder cancer in patients in conjunction with cystoscopy

These tests and other bladder tumor marker tests have low specificity. Urine is a dynamic fluid, and the results of a bladder tumor marker test can be influenced by conditions such as infection or hematuria affecting the composition of the urine. For this reason, no single bladder tumor marker has emerged as the generally accepted test of choice and none can be used as a screening tool for detecting bladder malignancy.

UroVysion™ (Abbott Molecular, Inc., Des Plaines, IL) is a multitarget FISH assay that detects aneuploidy in chromosomes 3, 7, and 17 as well as loss of 9p21 locus via FISH in urine. This test is used in conjunction with cystoscopy and cytology when results from these procedures are inconclusive.

There is insufficient published medical evidence to support the use of bladder tumor markers other than UroVysion™. There is limited evidence that the NMP22 test could help in a clinician’s decision making toward immediate versus delayed cystoscopy in patients with risk factors, signs/symptoms, and/or a history of bladder cancer.

Codes:

CPT Codes / HCPCS Codes / ICD-10 Codes	
Code	Description
CPT Codes	

MP.052.MH – Bladder Cancer Biomarker Tests

Policy Number: MP.052.MH
 Last Review Date: 05/10/2018
 Effective Date: 07/01/2018

88120	<i>Cytopathology, in situ hybridization (e.g. FISH), urinary tract specimen with morphometric analysis, 3-5 molecular probes, each specimen; manual (Urovysion™)</i>
ICD-10 codes covered if selection criteria are met:	
C67.0-C67.9	Malignant neoplasm of the bladder
C79.10-C79.11	Secondary malignant neoplasm of bladder
D09.0	Carcinoma in situ of bladder
D41.4	Neoplasm of uncertain behavior of bladder
D49.4	Neoplasm of unspecified behavior of bladder
R31.0-R31.9	Hematuria
Z85.51	Personal history of malignant neoplasm of the bladder

References

1. Bladder Cancer Clinical Guideline Update Panel. Guideline for the Management of Nonmuscle Invasive Bladder Cancer: (Stages Ta, T1, and Tis): 2007 Update. October 2007. Updated: Feb. 12, 2014. ©2007 American Urological Association. <http://www.auanet.org/common/pdf/education/clinical-guidance/Bladder-Cancer.pdf>
2. Centers for Medicare & Medicaid Services (CMS). Local Coverage Article: Biomarkers for Oncology (A52986). (Contractor: Novitas Solutions, Inc.). Revision Effective Date: 03/08/2018. <https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=52986&ver=93&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=All&Keyword=Biomarkers&KeywordLookup=Title&KeywordSearchType=And&bc=gAAAACAAAAAA&>
3. Centers for Medicare & Medicaid Services (CMS). Local Coverage Determinations (LCD) No. L35396. Biomarkers for Oncology. (Contractor: Novitas Solutions, Inc). Revision Effective Date: 03/08/2018. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35396&ver=148&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=All&Keyword=Biomarkers&KeywordLookup=Title&KeywordSearchType=And&bc=gAAAACAAAAAA&>
4. Clark, PE, Agarwal N, Biagiloi C, et al. Bladder Cancer. J Natl Comprehensive Cancer Netw, 2013 Apr; 11(4): 446-475. <http://www.jnccn.org/content/11/4/446.full.pdf+html>
5. Department of Health and Human Services. Agency for Healthcare Research and Quality. (AHRQ). National Guideline Clearinghouse (NGC). Screening for

MP.052.MH – Bladder Cancer Biomarker Tests

Policy Number: MP.052.MH
Last Review Date: 05/10/2018
Effective Date: 07/01/2018

- bladder cancer: U.S. Preventive Services Task Force recommendation statement. NGC# 8667. Last updated: October 12, 2011.
6. Department of Health and Human Services. Agency for Healthcare Research and Quality. (AHRQ). National Guideline Clearinghouse: Laboratory Medicine Practice Guidelines: Use of Tumor Markers, in Liver, Bladder, Cervical, and Gastric Cancers, NGC# 7967. Last updated: Dec. 8, 2010. [National Academy of Clinical Biochemistry].
<http://www.guideline.gov/content.aspx?id=23861&search=bladder+cancer+tumor+antigen+test>
 7. Eissa A, Swellam M, el-Mosallamy H, et al. Diagnostic value of urinary molecular markers in bladder cancer. *Anticancer Res* 2003 Sept-Oct; 23(5b):4347-4355.
<http://www.ncbi.nlm.nih.gov/pubmed/14666650>
 8. Goldstein M, Messing E. Prostate and Bladder Cancer Screening. *J Am Coll Surg*. 1998 Jan;186(1):63-74. http://ac.els-cdn.com/S1072751597001506/1-s2.0-S1072751597001506-main.pdf?tid=60a877ac-5151-11e3-9c89-0000aab0f02&acdnat=1384889750_1ecce0081da6ba126bc84d304933f41a
 9. Halling KC, King W, Sokolava IA. A comparison of BTA stat, hemoglobin dipstick and UroVysion assays for the detection of urothelial carcinoma in urine. *J Urol* 2002 May;167(5):2001-2006.
<http://www.sciencedirect.com/science/article/pii/S0022534705650720>
<http://www.guideline.gov/content.aspx?id=34289&search=bladder+cancer+biomarker>
 10. Hayes Annual Review Summary. Ancillary UroVysion Fluorescence In Situ Hybridization (FISH) Testing for Bladder Cancer Screening and Detection. July 18, 2012.
 11. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology-Bladder Cancer Version 2.2014. Released 2014 May 14.
http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
 12. Parker J, Spiess PE. Current and Emerging bladder Cancer Urinary Biomarkers. *TheScientificWorldJOURNAL*, May 26, 2011, 11: 1103-1112.
<http://www.hindawi.com/journals/tswj/2011/586467/abs/>
 13. Sapre N, Anderson PD, Costello AJ, et al. Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise? *Urol Oncol*. 2014 Jan;32(1):48.e9-17. doi: 10.1016/j.urolonc.2013.07.002. Epub 2013 Oct 17.
<http://www.sciencedirect.com/science/article/pii/S1078143913002895>
 14. U.S. Food and Drug Administration. Center of Devices and Radiologic Health. 510(k) Summary Letter: UroVysion™ Bladder Cancer Kit. P030052.
http://www.accessdata.fda.gov/cdrh_docs/pdf3/p030052a.pdf FDA for UroVysion 2005
 15. U.S. Food and Drug Administration. Recently-Approved Devices: UroVysion™ Bladder Cancer- P030052. Last updated: Sept. 4, 2013.

MP.052.MH – Bladder Cancer Biomarker Tests

Policy Number: MP.052.MH
Last Review Date: 05/10/2018
Effective Date: 07/01/2018

<http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm078663.htm>

16. Wiener HG, Mian C, Haitel A, et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998 Jun;159(6):1876-80 http://ac.els-cdn.com/S0022534701631847/1-s2.0-S0022534701631847-main.pdf?_tid=99a0a8b4-5155-11e3-9e82-00000aab0f6c&acdnat=1384891564_c04197441f580d37495f33c8581c770c
17. Xylinas E, Kluth LA, Rieken M, et al. Urine markers for detection and surveillance of bladder cancer. Urol Oncol. 2014 Apr;32(3):222-229. doi: 10.1016/j.urolonc.2013.06.001. Epub 2013 Sep 17. <http://www.sciencedirect.com/science/article/pii/S1078143913002500>

Disclaimer:

MedStar Health medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of MedStar Health and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

MedStar Health reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.